Search Results

You are looking at 61 - 70 of 654 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

Validation of the PREDICT Prognostication Tool in US Patients With Breast Cancer

Nickolas Stabellini, Lifen Cao, Christopher W. Towe, Megan E. Miller, Artur H. Sousa-Santos, Amanda L. Amin, and Alberto J. Montero

Background: PREDICT is an online prognostication tool derived from breast cancer registry information on approximately 6,000 women treated in the United Kingdom that estimates the postsurgical treatment benefit of surgery alone, chemotherapy, trastuzumab, endocrine therapy, and/or adjuvant bisphosphonates in early-stage breast cancer. Our aim was to validate the PREDICT algorithm in predicting 5- and 10-year overall survival (OS) probabilities using real-world outcomes among US patients with breast cancer. Methods: A retrospective study was performed including women diagnosed with unilateral breast cancer in 2004 through 2012. Women with primary unilateral invasive breast cancer were included. Patients with bilateral or metastatic breast cancer, no breast surgery, or missing critical clinical information were excluded. Prognostic scores from PREDICT were calculated and external validity was approached by assessing statistical discrimination through area under time-dependent receiver-operator curves (AUC) and comparing the predicted survival to the observed OS in relevant subgroups. Results: We included 708,652 women, with a median age of 58 years. Most patients were White (85.4%), non-Hispanic (88.4%), and diagnosed with estrogen receptor–positive breast cancer (79.6%). Approximately 50% of patients received adjuvant chemotherapy, 67% received adjuvant endocrine therapy, 60% underwent a partial mastectomy, and 59% had 1 to 5 axillary sentinel nodes removed. Median follow-up time was 97.7 months. The population’s 5- and 10-year OS were 89.7% and 78.7%, respectively. Estimated 5- and 10-year median survival with PREDICT were 88.3% and 73.8%, and an AUC of 0.77 and 0.76, respectively. PREDICT performed most poorly in patients with high Charlson-Deyo comorbidity scores (2–3), where PREDICT overestimated OS. Sensitivity analysis by year of diagnosis and HER2 status showed similar results. Conclusions: In this prognostic study utilizing the National Cancer Database, the PREDICT tool accurately predicted 5- and 10-year OS in a contemporary and diverse population of US patients with nonmetastatic breast cancer.

Full access

CRE24-041: Immunotherapy in Older Patients With Breast Cancer: Case Study and Literature Review

Carrie Sha, Marie Liu, Diana Lake, Jasmeet Singh, and Wanqing Iris Zhi

patients treated with immunotherapy and a focused literature review. Case Study: Five older women with TNBC, median age 75 (68–87), received pembrolizumab with chemotherapy at our single institution. Three early-stage TNBC patients received curative

Full access

EPR22-116: The Efficacy of COVID-19 Vaccination in Patients Receiving Chemo and Immunotherapies

Matthew Rendo, Chung Ting Kou, Jason Okulicz, Thomas Gibbons, Manuel Caballero, and Joshua Fenderson

INTRODUCTION : The National Cancer Comprehensive Network (NCCN) has advised vaccination against COVID-19 in all patients undergoing chemotherapy and immunotherapy. There is limited data on how cancer-targeted therapies impact COVID-19

Full access

YIA22-008: Identification of Biomarkers That Predict Responses to Immunotherapy in Merkel Cell Carcinoma

Yue Zhang, Zachary Zale Reinstein, Jasen Jackson, Kenneth Y Tsai, and Jaehyuk Choi

. The recent introduction of anti-PD1/PDL1 immunotherapy has revolutionized the treatment of MCC; however, ∼50% of patients do not respond. Investigating the mechanisms of response and resistance for otherwise fatal, advanced MCCs is an important

Full access

BPI20-021: Metastatic Renal Cell Carcinoma and Immunotherapy, Experience in a Third Level Hospital in Mexico City

Benigno Emmanuel Rodriguez Soto, Lorena López Zepeda, Daniela Vázquez Juarez, Alejandro Noguez Ramos, Alberto Villalobos Prieto, Samuel Rivera Rivera, Guillermo Manuel Olivares Beltrán, and Raquel Gerson Cwilich

patients a treatment option is immunotherapy, however limited access to this in our country makes relevant to report the results obtained in our practice and compare them with clinical trials. Objective: To report the experience of patients with metastatic

Full access

Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability–High Gastric Cancer: A Case Series

Louisa Liu, Yanghee Woo, Massimo D’Apuzzo, Laleh Melstrom, Mustafa Raoof, Yu Liang, Michelle Afkhami, Stanley R. Hamilton, and Joseph Chao

. Unlike in the adjuvant setting, neoadjuvant immunotherapy with a primary tumor in place may better induce early formation of immunologic memory, contributing to the eradication of MRD/micrometastases that exist after surgery. 14 – 16 In our series

Full access

Integrating Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Practical Evidence-Based Considerations

Cesar A. Santa-Maria, Maureen O’Donnell, Raquel Nunes, Jean L. Wright, and Vered Stearns

incorporate other adjuvant therapies. Several studies have demonstrated the benefit of adjuvant capecitabine, although these studies involved patients who did not receive neoadjuvant immunotherapy. 17 , 22 The KEYNOTE-522 regimen did not include

Full access

Long-Term Outcomes of dMMR/MSI-H Rectal Cancer Treated With Anti–PD-1–Based Immunotherapy as Curative-Intent Treatment

Jie-Hai Yu, Le-En Liao, Bin-Yi Xiao, Xuan Zhang, Ai-Wen Wu, Yong Cheng, Jing-Hua Tang, Wu Jiang, Ling-Heng Kong, Kai Han, Wei-Jian Mei, Zhi-Gang Hong, Wan-Jun Yang, Dan-Dan Li, Zhi-Zhong Pan, Yun-Feng Li, Xiao-Shi Zhang, and Pei-Rong Ding

after every 2 to 3 cycles of anti–PD-1 immunotherapy. cCR was defined as the absence of residual tumor on digital rectal examination, colonoscopy, and pelvic MRI, accompanied by a normal serum CEA level and negative findings on chest and abdominal CT

Full access

BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils

Zhuoran Tang, Chunyu Li, Peixin Chen, Haoyue Guo, Jinpeng Shi, Yingying Pan, Qi Wang, and Caicun Zhou

immunosuppressive receptors, and altering metabolic processes. Our findings highlighted the value of TANlncSig in TME as a marker of immune cell infiltration and showed the values of lncRNAs as indicators of immunotherapy. In conclusion, we used a machine learning

Full access

Optimizing Treatment for Head and Neck Cancers: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Presented by: Robert I. Haddad

affect the choice of first-line therapy include prior treatments and symptoms, as well as patient preference and logistics. And now, in the age of immunotherapy, the role of biomarkers plays an increasingly important role for certain patients. EXTREME